In addition, it is well established that patients treated with idelalisib have significant reductions in CCL3 and CCL4 and disruption of these networks results in significant migration of CLL cells out of lymph nodes. The gene discussed is CCL4; the disease is B-cell chronic lymphocytic leukemia.